# John C. Byrd

Source: https://onco.cc/people/john-byrd/  
OnCo record `john-byrd` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills.

## Summary

John Byrd (University of Cincinnati; formerly Ohio State) led the pivotal phase 1b/2 and RESONATE trials of ibrutinib in chronic lymphocytic leukaemia, the results that made BTK inhibition the standard of care and displaced chemoimmunotherapy, and the ELEVATE-RR head-to-head trial showing acalabrutinib is better tolerated. His laboratory helped develop acalabrutinib and continues work on resistance and AML therapeutics.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cll; btk; targeted-therapy
- Role: Chair, Department of Internal Medicine, University of Cincinnati College of Medicine
- Specialisms: Chronic lymphocytic leukaemia; BTK inhibitors; Drug development; Leukaemia biology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Byrd%20JC%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20ibrutinib

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- institutions: [University of Cincinnati Cancer Center](https://onco.cc/institutions/cincinnati-cancer-center/)
- trials: [Beat AML Master Trial](https://onco.cc/trials/beat-aml-master-trial/), [ELEVATE-TN](https://onco.cc/trials/elevate-tn/), [RESONATE](https://onco.cc/trials/resonate/)
- key papers: [ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL](https://onco.cc/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/)

---
JSON: https://onco.cc/api/v1/entities/john-byrd.json